Veru (VERU) Depreciation & Amortization (CF) (2010 - 2026)
Veru (VERU) posted quarterly Depreciation & Amortization (CF) of $28194.0 for Q1 2026, down 3.88% year-over-year from $29331.0 in Q1 2025, and little changed quarter-over-quarter from $28193.0 in Q4 2025.
Veru (VERU) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $28194.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 3.88% year-over-year to $28194.0; the TTM figure through Mar 2026 stood at $114291.0 (down 49.08% YoY), while the FY2025 annual figure was $152105.0, down 43.28% from the prior year.
- Depreciation & Amortization (CF) steadied at $28194.0 in Q1 2026 per VERU's latest filing, from $28193.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $146000.0 in Q2 2023 and bottomed at $28193.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $52697.2 across 5 years, with a median of $45000.0 in 2022.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) soared 274.36% — and 2025, when it sank 56.54%.
- Veru's Depreciation & Amortization (CF) stood at $45000.0 in 2022, then surged by 60.29% to $72129.0 in 2023, then declined by 10.06% to $64870.0 in 2024, then tumbled by 56.54% to $28193.0 in 2025, then advanced by 0.0% to $28194.0 in 2026.
- Business Quant data shows VERU's Depreciation & Amortization (CF) at $28194.0 in Q1 2026, $28193.0 in Q4 2025, and $28573.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 28,194.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,194.00 |
| Jun 30, 2026 | 28,194.00 |
| Mar 31, 2026 | 28,194.00 |
| Mar 31, 2026 | 28,194.00 |
| Dec 31, 2025 | 28,193.00 |
| Dec 31, 2025 | 28,193.00 |
| Sep 30, 2025 | 28,573.00 |
| Sep 30, 2025 | 28,573.00 |
| Jun 30, 2025 | 29,331.00 |
| Jun 30, 2025 | 29,331.00 |
| Mar 31, 2025 | 29,331.00 |
| Mar 31, 2025 | 29,331.00 |
| Dec 31, 2024 | 64,870.00 |
| Dec 31, 2024 | 64,870.00 |
| Sep 30, 2024 | 65,144.00 |
| Sep 30, 2024 | 65,144.00 |
| Jun 30, 2024 | 65,104.00 |
| Jun 30, 2024 | 65,104.00 |
| Mar 31, 2024 | 65,800.00 |
| Mar 31, 2024 | 65,800.00 |